BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 32269125)

  • 1. Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.
    Shibuya M; Aoshi T; Kuroda E; Yoshioka Y
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
    Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
    J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broadly Protective CD8
    Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
    J Virol; 2021 May; 95(12):. PubMed ID: 33827939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.
    Okuya K; Yoshida R; Manzoor R; Saito S; Suzuki T; Sasaki M; Saito T; Kida Y; Mori-Kajihara A; Kondoh T; Sato M; Kajihara M; Miyamoto H; Ichii O; Higashi H; Takada A
    J Virol; 2020 Jun; 94(12):. PubMed ID: 32269119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge.
    Moriyama M; Chino S; Ichinohe T
    Vaccine; 2017 Feb; 35(7):1001-1007. PubMed ID: 28111142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-Protective Potential and Protection-Relevant Immune Mechanisms of Whole Inactivated Influenza Virus Vaccines Are Determined by Adjuvants and Route of Immunization.
    Bhide Y; Dong W; Gribonika I; Voshart D; Meijerhof T; de Vries-Idema J; Norley S; Guilfoyle K; Skeldon S; Engelhardt OG; Boon L; Christensen D; Lycke N; Huckriede A
    Front Immunol; 2019; 10():646. PubMed ID: 30984200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs.
    Thomas M; Wang Z; Sreenivasan CC; Hause BM; Gourapura J Renukaradhya ; Li F; Francis DH; Kaushik RS; Khatri M
    Vaccine; 2015 Jan; 33(4):542-8. PubMed ID: 25437101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
    Shirai S; Shibuya M; Kawai A; Tamiya S; Munakata L; Omata D; Suzuki R; Aoshi T; Yoshioka Y
    Front Immunol; 2019; 10():3018. PubMed ID: 31998305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung.
    Proudfoot O; Esparon S; Tang CK; Laurie K; Barr I; Pietersz G
    BMC Infect Dis; 2015 Feb; 15():101. PubMed ID: 25887952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Interleukin-33-Group 2 Innate Lymphoid Cell Axis Represents a Potential Adjuvant Target To Increase the Cross-Protective Efficacy of Influenza Vaccine.
    Williams CM; Roy S; Califano D; McKenzie ANJ; Metzger DW; Furuya Y
    J Virol; 2021 Oct; 95(22):e0059821. PubMed ID: 34468174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity.
    Hong DK; Chang S; Botham CM; Giffon TD; Fairman J; Lewis DB
    J Virol; 2010 Dec; 84(24):12691-702. PubMed ID: 20943978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.
    Park BR; Subbiah J; Kim KH; Kwon YM; Oh J; Kim MC; Shin CH; Seong BL; Kang SM
    Virology; 2022 Jan; 566():143-152. PubMed ID: 34929590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.